Seoul, South Korea

Myoung-Suk Kim


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):

Title: Myoung-Suk Kim: Innovator in Biopolymer Conjugates

Introduction

Myoung-Suk Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biopolymers, particularly through his innovative patent related to interleukin-11 analogs. His work has implications for medical applications, showcasing the potential of biopolymer conjugates.

Latest Patents

Myoung-Suk Kim holds a patent for "Biopolymer conjugates comprising an interleukin-11 analog." This invention provides biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays enhanced resistance to acidolysis and shows increased stability compared to rhIL-11. The conjugates are characterized by a longer serum half-life and exhibit essentially no loss of activity compared to the corresponding unconjugated mIL-11. This patent highlights the advancements in biopolymer technology and its potential applications in therapeutics.

Career Highlights

Throughout his career, Myoung-Suk Kim has worked with notable companies such as Biopolymed Inc. and Viromed Co., Ltd. His experience in these organizations has contributed to his expertise in biopolymer research and development. His innovative approach has positioned him as a key figure in the field.

Collaborations

Myoung-Suk Kim has collaborated with talented individuals in his field, including Yuni Jung and Seong-Hyun Ho. These collaborations have fostered a productive environment for innovation and research.

Conclusion

Myoung-Suk Kim's contributions to the field of biopolymers, particularly through his patent on interleukin-11 analogs, demonstrate his commitment to advancing medical science. His work continues to influence the development of biocompatible materials for therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…